Type II collagen is a major component of cartilage. Heterozygous mutations in the type II collagen gene (COL2A1) result in a group of skeletal dysplasias known as Type II collagenopathy (COL2pathy). The understanding of COL2pathy is limited by difficulties in obtaining live chondrocytes. In the present study, we converted COL2pathy patients' fibroblasts directly into induced chondrogenic (iChon) cells. The COL2pathy-iChon cells showed suppressed expression of COL2A1 and significant apoptosis. A distended endoplasmic reticulum (ER) was detected, thus suggesting the adaptation of gene expression and cell death caused by excess ER stress. Chondrogenic supplementation adversely affected the chondrogenesis due to forced elevation of COL2A1 expression, suggesting that the application of chondrogenic drugs would worsen the disease condition. The application of a chemical chaperone increased the secretion of type II collagen, and partially rescued COL2pathy-iChon cells from apoptosis, suggesting that molecular chaperons serve as therapeutic drug candidates. We next generated induced pluripotent stem cells from COL2pathy fibroblasts. Chondrogenically differentiated COL2pathy-iPS cells showed apoptosis and increased expression of ER stress-markers. Finally, we generated teratomas by transplanting COL2pathy iPS cells into immunodeficient mice. The cartilage in the teratomas showed accumulation of type II collagen within cells, a distended ER, and sparse matrix, recapitulating the patient's cartilage. These COL2pathy models will be useful for pathophysiological studies and drug screening.
INTRODUCTION
The type II collagen produced by chondrocytes is the major component of the cartilage extracellular matrix (1) . The COL2A1 gene encodes the type II collagen a1 chain. Supramolecular assembly of three a1 chains to form trimer molecules occurs in the endoplasmic reticulum (ER) lumen (2) . The helical collagen molecules are trafficked via the Golgi network to the plasma membrane, and are then secreted into the extracellular space (3) . There, the collagen proteins are assembled into dense fibrils.
Heterozygous mutations of COL2A1 give rise to a spectrum of phenotypes predominantly affecting cartilage, collectively termed type II collagenopathies (COL2pathy) (4, 5) . Among them, achondrogenesis type II (ACGII) and hypochondrogenesis (HCG) are lethal due to respiratory insufficiency, which is secondary to an abnormal chest wall skeleton. Individuals with HCG show a less severe phenotype compared with those with ACGII. Patients with spondyloperipheral dysplasia (SPD) live into adulthood and show a combination of platyspondyly and brachydactyly and early onset osteoarthritis (6) .
Recent studies suggest that misfolded mutant collagens induce significant ER stress and trigger the ER stress signaling (7, 8) . Increased expression of ER stress markers, Grp94 and Chop, is observed in mice with an ENU-induced missense mutation in Col2a1 (9) . Apoptosis was detected in the chondrocytes of mice harboring a Col2a1 mutation (10) . Mouse models have enormously contributed to the understanding of COL2pathy. However, the clinical translation of the findings may be diminished by the differences in size and locomotion between mice and humans. For example, the thickness of articular cartilage in the distal femur is 2.2 mm in humans, whereas it is 0.030 mm in mice (11) . The volume density of chondrocytes in articular cartilage (chondrocytes + matrix) is about 2% in humans, whereas it is 15-40% in mice. The growth plate cartilage of humans and mice may also differ.
The emerging importance of the ER stress signaling in the pathology of COL2pathy offers the possibility of a new treatment strategy. If the misfolded protein load in the ER can be reduced to levels that can be managed by the cell, then the serious deleterious outcomes of an unresolved ER stress signaling, such as apoptosis, could be ameliorated (7) . One promising approach uses small chemical chaperones, which can stabilize proteins in their native conformation and rescue mutant protein folding and/or trafficking defects, but such agents have never been tested for COL2pathy.
With the development of induced pluripotent stem (iPS) cells, cardiomyocytes, neurons and hepatocytes can be obtained by the differentiation of iPS cells derived from patients with various diseases (12) (13) (14) . These cells, generated through iPS cells, may serve as a useful platform for exploring disease mechanisms and for drug screening. On the other hand, cells generated by directed conversion can also serve as a useful platform for exploring disease mechanisms, as neurons directly converted from skin fibroblasts from Alzheimer's disease patients recapitulated the pathophysiology of the disease (15) . We previously developed a method to convert mouse dermal fibroblasts (MDFs) (16) and human dermal fibroblasts (HDFs) (17) directly into chondrogenic cells named induced chondrogenic (iChon) cells by transducing fibroblasts with two reprogramming factors (c-Myc and Klf4) and one chondrogenic factor (Sox9). Cells do not undergo a pluripotent state during direct induction of iChon cells from fibroblast culture by transduction of c-Myc, Klf4 and SOX9 (18) . Human and mouse iChon cells express marker genes for chondrocytes but not fibroblasts and can form cartilage when transplanted into the subcutaneous spaces of immunodeficiency mice.
In order to provide live chondrocytes which recapitulate the features of COL2pathy, we generated chondrocytes from the HDFs of patients with COL2pathy using three different approaches: the induction of COL2pahty-iChon cells; the generation of COL2pathy-iPS cells, followed by chondrogenic differentiation and the generation of teratoma-containing cartilage from COL2pathy-iPS cells. These chondrocytes obtained through cellular reprogramming technologies suffered from abnormalities caused by excess ER stress and showed specific responses to reagents. The findings of our study may contribute to understanding the pathophysiology of the disease and to drug discovery for COL2pathy.
RESULTS

HDFs from patients with COL2pathy are normal
HDFs were obtained from two ACGII patients (ACGII-1 and ACGII-2), one HCG patient (HCG-1) and one SPD patient (SPD-1) (Supplementary Material, Table S1 ). The ACGII-2 patient showed an intermediate phenotype between ACGII and platyspondylic lethal skeletal dysplasia (PLSD)-Torrance type. Control HDFs from two different neonates were purchased (WT-1 and WT-2). A sequencing analysis of genomic DNA extracted from the patients' HDFs revealed heterozygous mutations in COL2A1 in all patients (Supplementary Material, Fig. S1A ). The ACGII-1 patient had a substitution mutation located at the acceptor site of exon 41. RT -PCR (Supplementary Material, Fig. S1B ) and a sequencing analysis revealed the existence of multiple lengths of short mRNAs lacking various combinations of exons, thus resulting in inframe deletion by exon skipping. HDFs from patients with COL2pathy (COL2pathy-HDFs) showed morphologies and proliferation rates similar to those of control HDFs (WT-HDFs) (Supplementary Material, Fig. S1C and D) . These results are consistent with the fact that neither WT-HDFs nor COL2pathy-HDFs express COL2A1 (Supplementary Material, Fig. S1E ). Accordingly, the transduction efficiencies did not differ between COL2pathy-HDFs and WT-HDFs (Supplementary Material, Fig. S1F ).
Disturbed chondrocytic maturation of COL2-pathy iChon cells
We converted COL2pathy-HDFs into iChon cells and investigated whether COL2pathy-iChon cells can be used for disease modeling. Transduction of COL2pathy-HDFs with c-MYC, KLF4 and SOX9 produced a few Alcian blue-positive nodules, whereas the transduction of WT-HDFs produced substantial numbers of Alcian blue-positive nodules 21 days after transduction (Day 21) (Fig. 1A and Supplementary Material, Fig. S2A ). The number of Alcian blue-positive nodules appeared to correlate with the severity of the diseases: ACGII-iChon cell culture showed a lower number of nodules than SPD-iChon cell culture. We next examined the iChon cells at earlier stages after transduction. By Day 7, WT-iChon cell colonies composed of polygonal-shaped cells had appeared (Fig. 1B , top panels; Supplementary Material, Movie S1). A polygonal shape is a characteristic of chondrocyte morphology, whereas HDFs are spindle-shaped. More than 90% of these polygonal cell colonies became condensed and subsequently multilayered, forming nodules by Day 13 ( We picked up iChon cell colonies and subjected them to a realtime RT -PCR expression analysis. The expression levels of SOX5 and SOX6, whose expression levels are induced by SOX9 (19) , were similarly activated in WT-iChon cells and COL2pathy-iChon cells on Day 14 compared with those of HDFs ( Fig. 1C and Supplementary Material, Fig. S2D ). The expression levels of SOX5 and SOX6 in WT-iChon cells and COL2pathy-iChon cells were comparable to those of redifferentiated fetal chondrocytes (HFC), thus suggesting that chondrogenic commitment occurs in COL2pathy-iChon cells, as well as in WT-iChon cells. COL2A1 transcription was initially activated similarly in WT-iChon cells and ACGII-2-iChon cells on Day 7 (Fig. 1D) . The expression levels of COL2A1 increased in WT-1-iChon cells as the time passed after transduction, The iChon cell colonies were picked up at various intervals after transduction and were subjected to a real-time RT -PCR expression analysis for COL2A1.
* P , 0.05, * * P , 0.01 compared with WT-1 (n ¼ 3). (E) The iChon cell colonies were picked up on Day 14 and were subjected to a real-time RT -PCR expression analysis for COL2A1.
* P , 0.05, * * P , 0.01 compared with WT-1 and WT-2 (n ¼ 3).
suggesting that WT-1-iChon cells undergo chondrocytic maturation. On the other hand, the COL2A1 expression in ACGII-2-iChon cells was suppressed as time passed on Days 14 and 21 ( Fig. 1D and E Fig. S3C ). The TUNEL assay revealed that more cells in COL2pathy-iChon cell colonies were TUNEL-positive than were the WT-iChon cell colonies around Day 15 ( Fig. 2A) . A transmission electron microscopic analysis revealed that the ER was distended in ACGII-2-iChon cells (Fig. 2B) on Day 14. The expression levels of BIP and CHOP were increased in COL2pathy-iChon cells on Day 18 ( Fig. 2C) , suggesting that there were increased ER stress signaling. The degree of increase was correlated with the severity of the patients' diseases. There are several pathways which transmit ER stress signals. XBP1 splicing was detected in COL2pathy-iChon cells but not in WT-iChon cells on Day 17 (Fig. 2D ), suggesting that the IRE1 pathway is involved in transmitting the ER stress. eIF2a was highly phosphorylated in the COL2pathy iChon cells compared with that in WT-iChon cells on Day 17 ( Fig. 2E) , suggesting that the PERK pathway is also involved in transmitting the ER stress. The expression levels of GRP94 were increased in COL2pathy-iChon cells compared with those in WT-iChon cells on Day 18 (Fig. 2C) , and cleaved ATF6 was detected in COL2pathy-iChon cells, but not in WTiChon cells on Day 17 (Fig. 2F) , suggesting that the ATF6 pathway is also involved in the transmission of ER stress. These results collectively suggest that COL2pathy-iChon cells have elevated ER stress and undergo apoptosis. Ascorbic acid is a co-factor for prolyl hydroxylase and facilitates collagen triple helix formation, but the iChon cells were induced using DMEM culture medium with 10% FBS without ascorbic acid. To confirm that type II collagen trimers were formed in the iChon cells, we performed a western blot analysis using anti-type II collagen antibodies under the non-reducing condition (without dithiothreitol and 2-mercaptethanol) using samples obtained from the iChon cells on Day 19. We detected type II collagen molecules with a size between 268 and 460 kDa in the lysates from COL2pathy-iChon cells, but not in the lysates from WT-iChon cells (Fig. 2G , left top panel). On the other hand, we detected type II collagen molecules with a size between 268 and 460 kDa in the supernatant from WT-iChon cell cultures, but it was minimally present in the supernatant from COL2pathy-iChon cell cultures (Fig. 2G , right panel). These results suggest that type II collagens were folded correctly in both WT-and COL2pathy-iChon cells, even when they were cultured in the absence of ascorbic acid. The folded type II collagen molecules were immediately secreted from WT-iChon cells, whereas misfolded type II collagen trimers were probably retained in the COL2pathy-iChon cells. These results collectively suggest that the excess ER stress in the COL2pahty-iChon cells is likely associated with the misfolding of type II collagen.
To confirm that the misfolding of mutant proteins is responsible for the abnormalities of the COL2pathy-iChon cells, we induced WT-and COL2pahty-iChon cells in the presence of ascorbic acid. We added ascorbic acid to the medium from Day 6 to Day 17 during the induction of WT-and COL2pathy-iChon cells, and subjected them to an analysis on Day 17. The application of ascorbic acid did not significantly change the number of Alcian blue-positive nodules in the WT-iChon cell culture, but did significantly decrease the numbers of Alcian blue-positive nodules in the ACGII-1-and HCG-1-iChon cell cultures (Fig. 3A) . The addition of ascorbic acid increased the expression levels of ER stress markers; BIP, GFP94 and CHOP, in the COL2pathy-iChon cells (Fig. 3B ). The presence of ascorbic acid in the culture did not affect the XBP1 splicing in either WT-or COL2pathy-iChon cells (Fig. 3C ). The administration of ascorbic acid increased the amount of phosphorylated eIF2a ( Fig. 3D ) and cleaved ATF6 (Fig. 3E ) in the COL2pathy-iChon cells. Therefore, the presence of ascorbic acid enhanced the abnormalities and increased the activation of ER stress pathways, including the PERK pathway and the ATF6 pathway, in COL2pathy iChon cells, supporting the idea that the misfolding of mutant proteins is responsible for the abnormalities of COL2pathy-iChon cells.
To examine how type II collagen molecules became degraded in the ACGII-iChon cells, we generated iChon cells in the presence of ascorbic acid, treated them with MG132 (a proteasome inhibitor) or bafilomycin A1 (a lysosome inhibitor), collected cell lysates and subjected them to a western blot analysis using an anti-type II collagen antibody (Fig. 3F ). The addition of bafilomycin A1 increased the amount of type II collagen, whereas the addition of MG132 did not, suggesting that there is lysosomal degradation of type II collagen.
Chondrogenic supplementation adversely affects COL2pathy-iChon cells
We analyzed how chondrogenic stimulation with BMP2 and TGFb1 (B + T) affects COL2pathy-iChon cells (Fig. 4A ). The addition of B + T to WT-iChon cell culture slightly increased the numbers of Alcian blue-positive nodules due to the chondrogenic effects of B + T ( COL2A1, including mutant COL2A1, thus resulting in an increased amount of misfolded protein and ER stress, which eventually led to the death of iChon cells and reduced the numbers of Alcian blue-positive nodules.
TMAO, a chemical chaperone, improved secretion of type II collagen and partially reduced apoptosis in COL2pathy-iChon cells
We then examined whether a chemical chaperone known to regulate protein folding could rescue the COL2pathy-iChon cells from abnormalities. The addition of trimethylamine N-oxide (TMAO) partially, but significantly, decreased the degree of apoptosis in COL2pathy-iChon cells (Fig. 4E ). The addition of TMAO increased the amount of extracellularly secreted type II collagen (Fig. 4F) , increased the Alcian blue staining (Supplementary Material, Fig. S4E ) and reduced the expression levels of ER stress-related markers, BIP, CHOP, GRP94, p58IPK and ERdj4 (Fig. 4G and Supplementary Material, Fig. S4F ), in COL2-pathy iChon cell culture. These results suggest that TMAO may stabilize the misfolded type II collagen molecules, leading to the improved secretion and accumulation of the extracellular molecules and rescuing cells from apoptosis in COL2pathy-iChon cell culture. 
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Generation of ACGII-and HCG-specific iPS cells
Another approach to modeling COL2pathy is the generation of iPS cells, followed by differentiation of these cells toward chondrocytes. This approach takes time, but has an advantage in that it can provide an almost unlimited supply of materials, because once iPS cells are established, they can be expanded indefinitely. We next generated iPS cells from the HDFs from two controls (WT-1 and WT-2), two ACGII patients (ACGII-1 and ACGII-2) and one HCG patient (HCG-1). We established three independent iPS cell lines (#) for each individual (Supplementary Material, Table S2 ). There were no obvious differences in the induction efficiency, cell morphologies (Fig. 5A) , expression levels of pluripotent markers (Fig. 5B and C) or pluripotency as indicated by teratoma formation (Fig. 5D) , between the WT-iPS cells, ACGII-iPS and HCG-iPS cells (Supplementary Material, Table S2 ). The karyotypes of the WT-iPS and ACGII-iPS cells examined were normal (Fig. 5E and Supplementary Material, Table S2 ). The ACGII-iPS and HCG-iPS cells were indistinguishable from control iPS cells, which was consistent with the fact that type II collagen is expressed by neither HDFs (Supplementary Material, Fig. S1E ) nor the resulting iPS cells (Fig. 5F ), and is unlikely to be expressed during the process of inducing the iPS cells.
In vitro differentiation of ACGII-iPS and HCG-iPS cells toward chondrocytes
We generated chondrocytes from iPS cells by following the previously described method (23) , with some modifications. The targeted differentiation of iPS cells toward prochondrogenic cells was performed by serially adding combinations of growth factors for 14 days (Supplementary Material, Fig. S5A ). The expression of pluripotency markers (OCT3/4 and NANOG) decreased, and the expression of mesoendodermal markers (T and KDR) transiently increased, in the WT-iPS, ACGII-iPS and HCG-iPS cells that underwent differentiation (Supplementary Material, Fig. S5B ). On Day 14, differentiated WT-iPS cells, ACGII-iPS and HCG-iPS cells were multilayered (Fig. 6A) . We then scraped the cells and subjected them to pellet culture for chondrogenic maturation. The expression levels of chondrocytic markers increased gradually in the differentiated WT-iPS cells, whereas the level increased slightly on Days 14 and 28 and decreased on Day 42 in the differentiated ACGII-iPS and HCG-iPS cells (Fig. 6B) . We then analyzed the pellets histologically. Cells were embedded in matrix, which was positively stained with safranin O, in the pellets generated from differentiated WT-iPS cells, whereas the pellets of differentiated ACGII-iPS cells were not stained with safranin O (Fig. 6C and Supplementary Material, Fig. S6 ). The cells in the pellets of differentiated ACGII-iPS cells underwent apoptosis, as indicated by their expression of cleaved caspase-3 and positive TUNEL staining (Fig. 6C) . The expression of ER stress markers in differentiated ACGII-iPS and HCG-iPS cells was significantly elevated compared with that in differentiated WT-iPS cells on Day 42 (Fig. 6D and Supplementary Material,  Fig. S5C ). Furthermore, TMAO reduced the expression of ER stress markers (Supplementary Material, Fig. S5D ). These results indicate that the chondrogenic differentiation of ACGII-iPS and HCG-iPS cells causes ER stress and apoptosis.
To determine which types of chondrocytic cells were generated by these two methods (induction of iChon cells and chondrogenic differentiation of iPS cells), we analyzed the expression of marker genes for growth plate cartilage and articular cartilage (Supplementary Material, Fig. S7 ). The WT-iChon cells and chondrogenically differentiated WT-iPS cells expressed markers for articular cartilage (PRG4 and CILP), but not markers for hypertrophic chondrocytes in the growth plate (COL10A1 and MMP13). These results suggest that the iChon cells and chondrogenically differentiated iPS cells may have the characteristics of articular chondrocytes or epiphyseal proliferative chondrocytes in primordial cartilage.
Modeling of ACGII-cartilage in teratomas in immunodeficient mice
We next examined the cartilage in teratomas formed by the transplantation of iPS cells into immunodeficient mice. A histological analysis of the teratomas revealed that cartilage tended to be smaller, and that the extracellular matrix was thinner and more weakly stained with safranin O in the teratomas formed by ACGII-iPS cells compared with the cartilage in teratomas formed by WT-iPS cells (Fig. 7A) . The chondrocytes were large in the teratomas formed by ACGII-iPS cells. These histological findings recapitulate the findings of cartilage obtained from ACGII patients at the time of autopsy (24, 25) .
An immunohistochemical analysis showed that type II collagen existed abundantly in the extracellular matrix, but not inside of cells, in the cartilage in the teratomas formed by WT-iPS cells (Fig. 7B, top panels) . On the other hand, type II collagen existed in a thin matrix in a reduced amount, and existed within the cells, in the cartilage in the teratomas formed by ACGII-iPS cells (Fig. 7B, bottom panels) . The type II collagen detected within these cells may correspond to the accumulation of misfolded type II collagen in the rER. Cartilage containing such chondrocytes bearing type II collagen within the cells were absent in the immunohistological sections of teratomas formed by control iPS cells (Fig. 7C ).
An electron microscopic analysis revealed a distended rER in the chondrocytes in the teratomas formed by ACGII-iPS cells (Fig. 7D) . The extracellular matrix showed reduced densities of collagen fibrils (Fig. 7E) . These results collectively demonstrate that COL2pathy-specific teratomas contain cartilage which recapitulates the cartilage tissue in patients with COL2pathy.
DISCUSSION
We herein performed disease modeling for type II collagenopathies using three approaches: (i) directed conversion from patient-specific HDFs to iChon cells; (ii) the generation of iPS cells from patient-specific HDFs, followed by the differentiation of these cells toward chondrocytes in vitro and (iii) the generation of iPS cells, followed by the formation of teratomas containing cartilage in mice. Using these approaches, the expected pathological features, such as elevated expression of ER stress markers, apoptosis, the retention of type II collagen within cells and abnormal ultrastructure of the extracellular matrix, were recapitulated. In addition, the severity of diseases tended to correlate with degrees of abnormalities in the COL2pathy-
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The cellular consequences of ER stress signaling are contextdependent, and range from adaptation to cell death, depending on the levels of ER stress signaling (8) . By analyzing iChon cell models of COL2pathy, we discovered several findings that may contribute to understanding the pathomechanics of COL2-pathy. The COL2pathy-iChon cells are chondrogenically committed, because the levels of SOX5 and SOX6 expression in the COL2pathy-iChon cells were similar to those in control iChon Fig. S2D ). The expression levels of COL2A1 gradually increased during the maturation of iChon cells (Fig. 1D) , probably resulting in an accumulation of mutant COL2A1 and unfolded protein in the rER in COL2pathy-iChon cells (Fig. 2B ). This caused ER stress signaling ( Fig. 2C-F) . When the ER stress is moderate, ER stress signaling may result in adaptations to reduce the expression of COL2A1 (Fig. 1D and E) and other cartilage matrix genes (Supplementary Material, Fig. S2E ) to decrease the amount of misfolded protein. When ER stress is further increased due to the maturation of iChon cells, the increased ER stress signaling may induce cell death ( Fig. 2A and Supplementary Material, Movie S1).
Controlling COL2A1 expression is important in the development of the disease phenotype
We found that the treatment of COL2pathy-iChon cells with BMP2 and TGFb1 inhibited the formation of chondrogenic nodules and caused cell loss ( Fig. 4A and C) . The treatment increased the expression of COL2A1 (Fig. 4D ) and probably mutant COL2A1, which likely resulted in increased ER stress. This finding could explain the abnormalities observed in tissue morphogenesis during development and growth in the individuals with COL2pathy, because prochondrogenesis factors, including BMPs and TGFbs, necessarily presage the emergence of a specific developmental phenotype. During the development and growth of COL2pathy patients, prechondrogenic cells may initially adapt to the ER stress. However, when the chondrogenic cells mature in response to exposure to growth factors, including BMPs and TGFbs, the expression of COL2A1 increases, increasing the ER stress beyond the limit of adaptation, triggering apoptotic signaling and the development of the disease phenotype. Thus, the ability of a cell to adapt to ER stress, and the nature of its adaptation strategies, can determine the disease phenotype.
Molecular chaperones can be a candidate therapeutic drug for COL2pathy
The adverse effects of BMP2 and TGFb1 on the survival of COL2pathy-iChon cells suggest that the application of chondrogenic drugs will likely worsen the symptoms in patients with COL2pathy. However, we also discovered that chemical chaperones may be a promising treatment, because TMAO decreased the apoptosis of COL2pathy-iChon cells (Fig. 4E) . TMAO is a natural chemical chaperone that directly acts on proteins in the unfolded state, thereby increasing the folding rate and stability of various mutant, otherwise labile, proteins (26) . This function of TMAO led to improved secretion of type II collagen (Fig. 4F) , decreasing ER stress in COL2pathy iChon cells ( Fig. 4G and Supplementary Material, Fig. S4F ) and differentiated COL2pa-thy iPS cells (Supplementary Material, Fig. S5D ). It remains to be analyzed whether TMAO can rescue the folding of type II collagen in COL2pathy iChon cells. Additional studies will be needed to screen for more effective chemical chaperones that substantially rescue these cells from apoptosis that may be clinically applicable.
COL2pathy-iChon cells, chondrogenically differentiated COL2pathy-iPS cells and cartilage in teratomas from COL2pathy-iPS cells can be used complementarily
We detected abnormalities in COL2pathy-iChon cells as early as Day 14. This is a relatively short-term culture, and given them an advantage compared with iPS cells, which take several months to generate and subsequently redifferentiate into chondrocytes.
Another advantage of this model is that a lot of iChon cell colonies can be obtained in each experiment. Time-lapse observations over the course of iChon cell induction showed that each iChon cell colony appears to be clonal (17, 18) , although it is possible that more than one cell may give rise to an iChon cell colony. Multiple colonies can be examined in iChon cell models, contributing to the reproducibility of the results. On the other hand, the abnormalities are exaggerated in iChon cell models. The formation of chondrogenic nodules from COL2pathy-iChon cells was severely reduced, whereas cartilage is still formed in COL2pathy patients, although to a lesser extent than healthy subjects. An advantage of using iPS cells is their ability to be expanded almost indefinitely, making it possible to use them for high-throughput drug screening.
We herein demonstrated that the cartilage in the teratomas generated from ACGII-iPS cells recapitulates the phenotypes seen in the cartilage of patients. The effects of candidate drug can be tested on human cartilage, by applying them to the mice harboring teratoma.
While useful for exploring pathologies that result from impaired protein trafficking, these cell-based models may have more limited utility when exploring pathologies that result from altered signaling between cells or between cells and matrix components. Matricellular signaling defects are emerging as an important pathogenic mechanism in skeletal diseases, and such defects are not well modeled in culture systems, because they do not yet recapitulate the complex structure of the mammalian growth plate and articular cartilages.
High-throughput screening, which requires a large number of cells may be performed using chondrogenically differentiated COL2Pathy-iPS cells. When the optimal category of therapeutic drug is determined (for example, molecular chaperone) and the numbers of compounds for screening are limited, the COL2pathy-iChon cells from fibroblasts can be used for the screening of these limited compounds. Such disease modeling by directed conversion of cells and iPS cells would also be useful for other skeletal dysplasias and cartilage diseases, and may have other applications for difficult to obtain tissues.
MATERIALS AND METHODS
Cell culture
COL2-pathy HDFs derived from four different patients (Supplementary Material, Table S1 ) were obtained from the cell banks of the Coriell Institute and Saitama Children's Medical Center. Control HDFs from two different neonates were purchased from KURABO (Strain #1439 and #789013). HDFs were cultured in DMEM (Sigma) with 10% FBS (Invitrogen), 50 U/ml penicillin and 50 mg/ml streptomycin. Human iChon cells were induced and maintained in DMEM (Sigma) with 10% FBS (Invitrogen), 50 U/ml penicillin and 50 mg/ml streptomycin. Human iPS cells were maintained in DMEM/F12 (Sigma) with 20% Knockout Serum Replacement (Invitrogen), 2 mM L-glutamine, 100 mM non-essential amino acids, 100 mM b-mercaptoethanol, 4 ng/ml bFGF (Wako), 50 U/ml penicillin and 50 mg/ml streptomycin on mitomycin-C-treated mouse embryonic fibroblasts.
Generation of iChon cells
Retroviral transduction was performed as described (17) . Briefly, after nucleofection of the mouse slc7a1 gene (Takahashi et al., 2007) , human fibroblasts were infected with retroviruses encoding c-MYC, KLF4 and SOX9 using Plat-E cells and the pMX system (Day 0). The next day, the infected fibroblasts (1 × 10 5 cells) were re-seeded into 100 mm dishes (Day 1), unless otherwise specified. In the case of iChon cell colony expansion, the infected fibroblasts (2 × 10 4 cells) were re-seeded into 100 mm dishes, and iChon cell colonies were picked up using 200 ml pipettes under a microscope, and were then re-seeded into the wells of a 24-well plate. The iChon cells were generated and maintained in DMEM supplemented with 10% FBS, unless otherwise specified. In the experiments shown in Figure 3 , 50 mg/ml of ascorbic acid (Nacalai) or vehicle (water) was added to the medium from Day 6 to Day 17, and cells were subjected to an analysis on Day 17.
Alcian blue and toluidine blue staining
Cells were fixed in 100% methanol (Nacalai Tesque, Japan) for 2 min at 2208C, stained with pH 2.5 Alcian blue (Merck) or pH 4.1 toluidine blue (Wako) for 2 h at 258C, and washed three times with distilled water. The Alcian blue-or toluidine blue-positive colony numbers were counted using the NIS Element software program (Nikon). We defined a colony as a cell cluster that was more than 0.5 mm in diameter.
Immunofluorescence iChon cells were cultured on slides, fixed in 4% paraformaldehyde for 15 min at 258C, washed three times with PBS and blocked for 18 h in PBS containing 0.3% BSA (Sigma) and 0.1% Triton X-100 (Nacalai) at 48C. Primary antibodies against COL2A1 (Collagen II Ab-2, Thermo scientific), SSEA4 (ab16287, abcam) and TRA-1-60 (ab16288, abcam) in PBS containing 0.3% BSA and 0.1% Triton X-100 were applied for 1 h at 258C. After washing the samples three times with PBS, secondary antibodies were applied for 1 h at 258C.
RT -PCR and real-time RT -PCR analyses
The total RNA was extracted using RNeasy Mini Kits (Qiagen) or TRIzol (Invitrogen). The total RNAs prepared from the redifferentiated human primary fetal chondrocytes (HFC) were purchased from Cell Applications, Inc. (402RD-R10f). RT -PCR and real-time quantitative RT -PCR were performed as described previously (16) . Briefly, 100 ng of total RNA was used to synthesize the first-strand cDNA (20 ml scale) that was used as a template (2 ml after 1:5 dilution) for RT-PCR and realtime RT -PCR. Real-time RT -PCR was performed in 384-well plates using the Step-One-Plus real-time PCR system (Applied Biosystem). Normalized expression levels were calculated using the comparative CT method, with the GAPDH mRNA expression level used as internal control. The primers used for realtime RT -PCR are listed in Supplementary Material, Table S3 . 
TUNEL assay
iChon cell colonies were fixed in freshly prepared 4% paraformaldehyde for 1 h at 258C. An in situ cell death detection kit (TMR red; Roche) was used according to the manufacturer's instructions. The ratio of TUNEL positive cells to the total cells in one iChon colony was calculated in this study. The numbers of colonies examined are indicated in the figure legends.
Antibodies and inhibitors
The primary antibodies against COL2A1 (Santa Cruz), phosphoeIF2a (Cell Signaling), ATF6 (abcam), GAPDH (Santa Cruz), and b-Actin (Cell Signaling) were applied for the western blot analyses using total cell extracts and supernatants prepared from iChon cell cultures. Alkaline phosphatase-conjugated secondary antibodies were purchased from Invitrogen. MG132 (Abcam) and bafilomycin A1 (Abcam) were used as the proteasome and lysosome inhibitors, respectively, as described in a previous report (27) . We treated iChon cells with final concentration of 4 mM MG132 or 200 nM bafilomycin A1 for 18 h.
Western blot
Samples were subjected to electrophoresis in 3 -8% TrisAcetate gels (Invitrogen) in the absence of dithiothreitol and 2-mercaptethanol (under non-reducing condition) to detect type II collagen, and in gradient 4-12% Bis -Tris gels (Invitrogen) in the presence of 200 mM dithiothreitol after boiling for 5 min at 958C to detect phospho-eIF2a and ATF6. The separated proteins were transferred to nitrocellulose membranes and incubated for 1 h at 258C in 5% skim milk. The indicated primary antibodies (COL2A1 at a dilution of 1:200, phospho-eIF2a at 1:1000, ATF6 at 1:500, and GAPDH and b-Actin at 1:2000) were applied for 18 h at 48C. After washing the samples three times with PBS, alkaline phosphatase-conjugated secondary antibodies (1:2000) were applied for 1 h at 258C. After washing the membranes, the proteins were detected by the 4-nitro-bluetetrazolium-chloride and 5-bromo-4-chloro-3-indolyl-phosphate reactions.
Preparation of TMAO
The stock TMAO (Tokyo chemical industry, Japan) solution was prepared by dissolving TMAO in distilled water at a concentration of 5 M. Aliquots of stock TMAO/water solutions were added to the culture medium. As a control, an equal amount of water was added to the medium. A total of 50 mg/ml ascorbic acid was added in addition to the medium in the experiment of Supplementary Material, Figure S4D .
Preparation of chondrogenic supplements
Chondrogenic supplementation was performed using 50 ng/ml BMP2 and 10 ng/ml TGFb1 as a working concentration. Stock solutions of the chondrogenic supplements were prepared at ×1000 concentration in PBS containing 0.1% BSA, and were added to the culture medium. As a control, an equal volume of PBS containing 0.1% BSA was added to the medium.
Generation of human iPS cells and teratomas
Episomal plasmid vectors (Mixture Y4: OCT3/4, SOX2, KLF4, L-MYC, LIN28, and p53 shRNA) were electroporated into Human Molecular Genetics, 2015, Vol. 24, No. 2 311 human fibroblasts (28) with the Neon transfection system (Invitrogen). A week after transduction, 1 × 10 5 cells were re-seeded into 100 mm dishes with feeders. The cells were subsequently cultured in hiPS medium. To form teratomas, we injected 1 × 10 6 hiPS cells into the testicular capsules of BALB/c AJcl-nu/ nu male mice. Then, 6 -8 weeks later, tumors were cut into 5 mm pieces and fixed in 10% formalin. The tissue was embedded in paraffin and stained with hematoxylin and eosin.
In vitro chondrogenic differentiation of human iPS cells
Chondrogenic differentiation was performed following a previous report (23) , with some modifications. To remove feeder cells, iPS cells were seeded and cultured in ReproFF2 (Repro-CELL) medium on matrigel-coated dishes for two or three passages. After removing feeders (Day 0), the iPS cells were cultured in RPMI 1640 (Days 1 -3) or DMEM (Days 4 -14) supplemented with 1% FBS and human recombinant proteins (25 ng/ml WNT3A (R&D), 25 ng/ml Activin-A (R&D), 20 ng/ ml FGF2 (R&D), 10 ng/ml TGFb1 (Peprotech), 40 ng/ml BMP2 (Astellas, Japan) and 100 ng/ml GDF5 (PTT) (Supplementary Material, Fig. S5A ). Differentiated cells were scraped on Day 14, and 5 × 10 5 cells were centrifuged at 500 g for 10 min in a 15 ml tube. Pellets were cultured in DMEM with 10% FBS, 50 mg/ml ascorbic acid, 10 ng/ml TGFb1, 10 27 M dexamethasone, 100 mg/ml sodium pyruvate and ITS (10 mg/ ml insulin, 5.5 mg/ml transferrin and 6.7 ng/ml sodium selenite) for 4 weeks (Days 14-42).
Immunohistochemical staining
Teratoma formation was induced using six control iPS and six ACGII iPS cell lines. Semi-serial histological sections generated from formalin-fixed teratomas were immunostained with the primary and secondary antibodies. For a positive control, sections obtained from the joint capsule of a knee from a rat were used to test the anti-type II antibodies (SBA-1320-01, BIOZOL).
Electron microscopy
Teratomas or iChon cells were fixed with 4% paraformaldehyde and 2% glutaraldehyde. Post-fixation was performed with 2% osmium tetroxide. In the case of the teratoma analysis, cartilage tissues were found according to the morphology of cells and toluidine blue staining. After dehydration, embedding and polymerization, ultrathin sections were stained with 2% uranyl acetate. They were observed with a HITACHI 7650 electron microscope at an acceleration voltage of 80 kV.
Statistical analysis
The data are shown as averages and standard deviations. In this study, we used two-tailed Student's t-tests or one-way ANOVA (analysis of variance) with a Tukey -Kramer post-hoc test for multiple comparisons. P-values ,0.05 were considered to be statistically significant.
All experiments were approved by the institutional review board of Kyoto University and the institutional biosafety committee of Kyoto University.
